Metformin use and cirrhotic decompensation in patients with type 2 diabetes and liver cirrhosis.

ABSTRACT:

Aims

To compare the risks of all-cause mortality, hepatic outcomes, major adverse cardiovascular events between metformin users and nonusers for patients with diabetes and cirrhosis.

Methods

From the Taiwan's National Health Insurance Research Database, we selected propensity-score matched metformin users and nonusers from the cohorts of type 2 diabetes mellitus with compensated (n = 26 164) or decompensated liver cirrhosis (n = 15 056) between 1 January 2000 and 31 December 2009, and followed them until 31 December 2010. Cox proportional hazards models with robust sandwich standard error estimates were used to assess risk of investigated outcomes for metformin users.

Results

The incidence rates of mortality during follow-up were 3.8 and 3.3 per 100 patient-years (adj

SUBMITTER: Yen FS 

PROVIDER: S-EPMC9292486 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature